Articles related to Pathology

In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).

Published on the AUA website and developed by a panel of experts from these three groups as well as representation from the American Society of Clinical Oncology (ASCO) and a patient advocate, 38 recommendations are listed across the care continuum of advanced disease.

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.

Gastrointestinal and breast cancer sessions were featured on the first day of the virtual conference, highlighting practice-changing results from a multitude of studies, including the HER2CLIMB, MINDACT, and PHERGAIN trials.

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.